questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes",
"headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Extracellular Signal-Regulated MAP Kinases",
"url": "https://questionsmedicales.fr/mesh/D048049",
"about": {
"@type": "MedicalCondition",
"name": "Extracellular Signal-Regulated MAP Kinases",
"code": {
"@type": "MedicalCode",
"code": "D048049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3",
"alternateName": "Mitogen-Activated Protein Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048052",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Wang",
"url": "https://questionsmedicales.fr/author/Juan%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Mohammad Shafiq",
"url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Kumaravelu Jagavelu",
"url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Neeraj Kumar Verma",
"url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Jimut Kanti Ghosh",
"url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Expert consensus on regenerative endodontic procedures.",
"datePublished": "2022-12-01",
"url": "https://questionsmedicales.fr/article/36450715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41368-022-00206-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "SEED Consensus Document on SpyGlass-DS.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36179947",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gastrohep.2022.08.012"
}
},
{
"@type": "ScholarlyArticle",
"name": "SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).",
"datePublished": "2023-03-24",
"url": "https://questionsmedicales.fr/article/36995888",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/S0004-2803.2022005S1-02"
}
},
{
"@type": "ScholarlyArticle",
"name": "[The German S3 guidelines on prevention of coercion and treatment of aggressive behavior: from evidence to consensus, from consensus to implementation].",
"datePublished": "2023-03-20",
"url": "https://questionsmedicales.fr/article/36939857",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00115-023-01461-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dutch Consensus Paper: A Consensus View on the Place of Neurostimulation Within the Treatment Arsenal of Five Reimbursed Indications for Neurostimulation in The Netherlands.",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/35562262",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neurom.2022.02.232"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D020928"
},
{
"@type": "ListItem",
"position": 7,
"name": "Extracellular Signal-Regulated MAP Kinases",
"item": "https://questionsmedicales.fr/mesh/D048049"
},
{
"@type": "ListItem",
"position": 8,
"name": "Mitogen-Activated Protein Kinase 3",
"item": "https://questionsmedicales.fr/mesh/D048052"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3",
"description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Consensus&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitogen-Activated Protein Kinase 3",
"description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Consensus&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitogen-Activated Protein Kinase 3",
"description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Consensus&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitogen-Activated Protein Kinase 3",
"description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Consensus&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitogen-Activated Protein Kinase 3",
"description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Consensus&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3",
"description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Consensus&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de MAPK3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer MAPK3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de phosphorylation et les analyses protéomiques sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à MAPK3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est liée à des cancers et des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner une inflammation et des douleurs."
}
},
{
"@type": "Question",
"name": "MAPK3 affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à MAPK3 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de MAPK3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour MAPK3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter MAPK3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Des exercices spécifiques aident-ils MAPK3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3."
}
},
{
"@type": "Question",
"name": "La gestion du poids influence-t-elle MAPK3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent MAPK3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle corriger MAPK3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent la voie MAPK3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour MAPK3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle MAPK3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle liée à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment MAPK3 affecte-t-elle le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "MAPK3 peut-elle influencer le vieillissement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à MAPK3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'activité de MAPK3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il MAPK3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles affecter MAPK3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber la signalisation de MAPK3."
}
}
]
}
]
}
Regenerative endodontic procedures (REPs) is a biologic-based treatment modality for immature permanent teeth diagnosed with pulp necrosis. The ultimate objective of REPs is to regenerate the pulp-den...
Endoscopic retrograde cholangiopancreatography (ERCP) is the technique of choice for the treatment of biliopancreatic pathology. However, fluoroscopic imaging does not always allow an adequate diagnos...
Inflammatory bowel disease (IBD) is an immune-mediated disorder that includes Crohn's disease (CD) and ulcerative colitis. CD is characterized by a transmural intestinal involvement from the mouth to ...
To guide the safest and effective medical treatments of adults with CD....
This consensus was developed by stakeholders representing Brazilian gastroenterologists and colorectal surgeons (Brazilian Organization for Crohn's disease and Colitis (GEDIIB)). A systematic review o...
The medical recommendations (pharmacological and non-pharmacological interventions) were mapped according to the stage of treatment and severity of the disease in three domains: management and treatme...
The German S3 guidelines on prevention of coercion: prevention and therapy of aggressive behavior in adults (2018) are cross-sectional guidelines that in addition to medical scientific evidence also t...
After an interpretation trajectory, the Dutch Quality of Healthcare Institute recommended that for five indications, spinal cord stimulation, dorsal root ganglion stimulation, or occipital nerve stimu...
A scientific committee, consisting of three anesthesiologists/pain physicians (one of whom acted as the working group's chair), a neurosurgeon, a neurologist, a rehabilitation physician, and three nur...
For all five diagnoses, general and diagnosis-specific treatment requirements, conservative treatments, and minimally invasive treatments are listed. These treatments should be considered in the chron...
The content of this consensus view was discussed and compared with other literature on cost-effectiveness and the place in the algorithm of treating chronic pain. This Dutch consensus paper could ulti...
Approximately 25% of patients with inflammatory bowel disease (IBD) develop the disease during childhood or adolescence and treatment aims to control active symptoms and prevent long-term complication...
This consensus aims to provide guidance on the most effective medical and surgical management of pediatric patients with CD or UC....
Experts in Pediatric IBD representing Brazilian gastroenterologists (Brazilian Organization for Crohn's Disease and Colitis [GEDIIB]) developed this consensus. A rapid review was performed to support ...
The recommendations are presented according to the stage of treatment and severity of the disease in three domains: management and treatment (drug and surgical interventions), criteria for evaluating ...
After 2020, clinical practice recommendations have been released to inform cardiac rehabilitation (CR) programs of best practices for post-COVID programming. The objective of this systematic review wa...
Five databases (March 2020 through April 2023), grey literature and Web sites of CR international associations were searched. Inclusion criteria were local, national, and international association-end...
Overall, 4890 records were identified; 4 CPGs, 9 position/scientific statements, and 6 expert/Delphi consensus papers were included. All guidelines/statements included information related to program d...
Although 19 documents were identified, CR delivery in low resource settings and for culturally and linguistically diverse populations require attention. Additionally, few recommendations on nutrition,...
The COVID-19 pandemic provides a unique opportunity to study science communication and, in particular, the transmission of consensus. In this study, we show how "science communicators," writ large to ...
Consensus Panel 1 (CP1) of the 11...
In recent years, HIV testing frequency has increased, resulting in more people being diagnosed during seroconversion with a temporarily low CD4 count. Using the current consensus definition of late HI...
In spring 2022, a European expert group convened to revise the current late HIV presentation consensus definition. A survey on data availability to apply this revised definition was sent to nominated ...
Experts agreed that the updated definition should refer to late HIV diagnosis rather than presentation and include the following addition: People with evidence of recent infection should be reclassifi...
Accurate data on late diagnosis are important to describe the effects of testing programmes. Reclassification of individuals with recent infection will help to better identify populations most at risk...